What initial and terminal elimination half-lives were reported for idarucizumab after a 5 g intravenous infusion in healthy adults aged 45–64 years?

In six healthy adults aged 45–64 years receiving idarucizumab as a 5 g intravenous infusion, the initial elimination half-life was 47 minutes (gCV 11.4%) and the terminal half-life was 10.3 hours (gCV 18.9%).